Sinil Pharmaceutical Co (XKRX:012790) ROCE % : 12.00% (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Sinil Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sinil Pharmaceutical Co's annualized ROCE % for the quarter that ended in Dec. 2024 was 12.00%.

Sinil Pharmaceutical Co ROCE % Historical Data

The historical data trend for Sinil Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinil Pharmaceutical Co ROCE % Chart

Sinil Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

7.39

7.22

12.02

11.30

11.51

Sinil Pharmaceutical Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															15.48	11.85	12.56	8.30	12.00

Sinil Pharmaceutical Co ROCE % Calculation

Sinil Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	16564.872	/	( ( (152459.585 - 14144.528)	+	(165861.375 - 16452.857) )	/ 2 )
	=	16564.872	/	( (138315.057	+	149408.518)	/ 2 )
	=	16564.872	/	143861.7875
	=	11.51 %

Sinil Pharmaceutical Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	17719.928	/	( ( (160360.283 - 14553.976)	+	(165861.375 - 16452.857) )	/ 2 )
	=	17719.928	/	( ( 145806.307	+	149408.518 )	/ 2 )
	=	17719.928	/	147607.4125
	=	12.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Sinil Pharmaceutical Co (XKRX:012790) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sinil Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Sinil Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinil Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinil Pharmaceutical Co Ltd (XKRX:012790) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

315-18, Jangan-2 Dong, Dongdaemun-gu, Seoul, KOR, 380-860

Website

http://www.sinilpharm.com

Sinil Pharmaceutical Co Ltd is a South Korean drug manufacturing company. The products of the company include diphene gel, tour pen plasta, oriental herb tea cold liquid, and griffen ssung.

Sinil Pharmaceutical Co Headlines

No Headlines